Positive inotropic and lusitropic effects of HNO/NO− in failing hearts: Independence from β-adrenergic signaling

Nitroxyl anion (HNO/NO−), the one-electron reduced form of nitric oxide (NO), induces positive cardiac inotropy and selective venodilation in the normal in vivo circulation. Here we tested whether HNO/NO− augments systolic and diastolic function of failing hearts, and whether contrary to NO/nitrates such modulation enhances rather than blunts β-adrenergic stimulation and is accompanied by increased plasma calcitonin gene-related peptide (CGRP). HNO/NO− generated by Angelis' salt (AS) was infused (10 μg/kg per min, i.v.) to conscious dogs with cardiac failure induced by chronic tachycardia pacing. AS nearly doubled contractility, enhanced relaxation, and lowered cardiac preload and afterload (all P < 0.001) without altering plasma cGMP. This contrasted to modest systolic depression induced by an NO donor diethylamine(DEA)/NO or nitroglycerin (NTG). Cardiotropic changes from AS were similar in failing hearts as in controls despite depressed β-adrenergic and calcium signaling in the former. Inotropic effects of AS were additive to dobutamine, whereas DEA/NO blunted β-stimulation and NTG was neutral. Administration of propranolol to nonfailing hearts fully blocked isoproterenol stimulation but had minimal effect on AS inotropy and enhanced lusitropy. Arterial plasma CGRP rose 3-fold with AS but was unaltered by DEA/NO or NTG, supporting a proposed role of this peptide to HNO/NO− cardiotropic action. Thus, HNO/NO− has positive inotropic and lusitropic action, which unlike NO/nitrates is independent and additive to β-adrenergic stimulation and stimulates CGRP release. This suggests potential of HNO/NO− donors for the treatment of heart failure.

[1]  Pawan K. Singal,et al.  Oxidative stress and heart failure , 1995, Molecular and Cellular Biochemistry.

[2]  D. Kass,et al.  Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. , 2003, Free radical biology & medicine.

[3]  J. Bronzwaer,et al.  Myocardial contractile effects of nitric oxide. , 2002 .

[4]  K. Houk,et al.  The reduction potential of nitric oxide (NO) and its importance to NO biochemistry , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  N. Freemantle,et al.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysis , 2002, European journal of heart failure.

[6]  R. Bache,et al.  Nitric Oxide Modulates Myocardial Oxygen Consumption in the Failing Heart , 2002, Circulation.

[7]  R. Ventura-clapier,et al.  Increased myocardial expression of RAMP1 and RAMP3 in rats with chronic heart failure. , 2002, Biochemical and biophysical research communications.

[8]  Jun Peng,et al.  The cardioprotection of calcitonin gene-related peptide-mediated preconditioning. , 2002, European journal of pharmacology.

[9]  A. Shah,et al.  Role of cyclic GMP‐dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes , 2002, The Journal of physiology.

[10]  Joao A. C. Lima,et al.  Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. , 2002 .

[11]  D. Kass,et al.  Imbalance Between Xanthine Oxidase and Nitric Oxide Synthase Signaling Pathways Underlies Mechanoenergetic Uncoupling in the Failing Heart , 2002, Circulation research.

[12]  R. Maestri,et al.  Chronic infusion of dobutamine and nitroprusside in patients with end‐stage heart failure awaiting heart transplantation: safety and clinical outcome , 2001, European journal of heart failure.

[13]  D. Sane,et al.  Upregulation of Functional &bgr;3-Adrenergic Receptor in the Failing Canine Myocardium , 2001, Circulation research.

[14]  D. Kass,et al.  Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  J. Balligand,et al.  Upregulation of &bgr;3-Adrenoceptors and Altered Contractile Response to Inotropic Amines in Human Failing Myocardium , 2001, Circulation.

[17]  D. Wink,et al.  Unique Oxidative Mechanisms for the Reactive Nitrogen Oxide Species, Nitroxyl Anion* , 2001, The Journal of Biological Chemistry.

[18]  B. Brenner,et al.  Increased gene expression of adrenomedullin and adrenomedullin-receptor complexes, receptor-activity modifying protein (RAMP)2 and calcitonin-receptor-like receptor (CRLR) in the hearts of rats with congestive heart failure. , 2000, Clinical science.

[19]  Alpar,et al.  Neuropeptide variability in man , 2000, European journal of clinical investigation.

[20]  D. Kass,et al.  Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. , 2000, Circulation research.

[21]  T. Shinke,et al.  Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. , 2000, Circulation.

[22]  D. Kass,et al.  Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033. , 2000, Circulation.

[23]  F. Gao,et al.  Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Balligand Regulation of cardiac beta-adrenergic response by nitric oxide. , 1999, Cardiovascular research.

[25]  E. Lakatta,et al.  Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. , 1999, Circulation research.

[26]  R. Winslow,et al.  Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies. , 1999, Circulation research.

[27]  I. Zucker,et al.  Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. , 1999, Circulation research.

[28]  J. Stamler,et al.  NOS: Modulator, not mediator of cardiac performance , 1999, Nature Medicine.

[29]  A. Franco‐Cereceda,et al.  Calcitonin gene-related peptide in myocardial ischaemia and reperfusion in the pig. , 1998, Cardiovascular research.

[30]  James B. Mitchell,et al.  The cytotoxicity of nitroxyl: possible implications for the pathophysiological role of NO. , 1998, Archives of biochemistry and biophysics.

[31]  M. Creager,et al.  Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. , 1998, Circulation.

[32]  D. Kass,et al.  Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. , 1997, Journal of the American College of Cardiology.

[33]  M. Redfield,et al.  Angiotensin II in the evolution of experimental heart failure. , 1996, Hypertension.

[34]  Y. Ishikawa,et al.  β‐ADRENOCEPTOR DESENSITIZATION DURING THE DEVELOPMENT OF CANINE PACING‐INDUCED HEART FAILURE , 1996, Clinical and experimental pharmacology & physiology.

[35]  M. Creager,et al.  Arterial baroreflex regulation of blood pressure in patients with congestive heart failure. , 1994, Journal of the American College of Cardiology.

[36]  M. Feldman,et al.  Bolus intravenous nitroglycerin predominantly reduces afterload in patients with excessive arterial elastance. , 1993, Journal of the American College of Cardiology.

[37]  M. Komajda,et al.  Plasma calcitonin gene-related peptide decreases in chronic congestive heart failure. , 1992, European heart journal.

[38]  C. Gennari,et al.  Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure. , 1990, Cardiovascular research.

[39]  L. Opie Drugs for the Heart , 1981 .